HCM
BCTXZ

Heights Capital Management’s BriaCell Therapeutics Corp Warrant BCTXZ Stock Holding History

Heights Capital Management’s Portfolio BCTXZ Stock Details BCTXZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.3K Sell
313,379
-226,719
-42% -$22.1K 0.01% 234
2026
Q1 		$75.6K Sell
540,098
-4,600
-0.8% -$772 0.02% 172
2025
Q4 		$163K Hold
544,698
– – 0.06% 121
2025
Q3 		$186K Sell
544,698
-7,383
-1% -$2.45K 0.05% 111
2025
Q2 		$574K Buy
+552,081
New +$596K 0.15% 69

Other funds holding BCTXZ

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Heights Capital Management's BCTXZ Position: Q2 2026 in Review

Heights Capital Management reduced its BriaCell Therapeutics Corp Warrant (BCTXZ) stake by 42% in Q2 2026, selling an estimated $22.1K and leaving 313,379 shares worth $31.3K. The position accounts for 0.01% of the portfolio, ranked #234.

Heights Capital Management first reported a position in BCTXZ in Q2 2025 and has held it in 5 quarters since. The position peaked at $574K in Q2 2025. 5 funds tracked by Wall St. Rank hold BCTXZ as of Q2 2026.

  • Heights Capital Management held 313,379 shares of BriaCell Therapeutics Corp Warrant worth $31.3K as of Q2 2026.
  • Heights Capital Management sold 226,719 BriaCell Therapeutics Corp Warrant shares in Q2 2026, an estimated $22.1K.
  • BriaCell Therapeutics Corp Warrant made up 0.01% of Heights Capital Management's portfolio in Q2 2026, its #234 holding.
  • Heights Capital Management first reported a position in BriaCell Therapeutics Corp Warrant in Q2 2025 and has held it in 5 quarters since.
  • Heights Capital Management's BriaCell Therapeutics Corp Warrant position peaked at $574K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held BriaCell Therapeutics Corp Warrant as of Q2 2026.

Based on Heights Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.